{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:30:41Z","timestamp":1754159441986,"version":"3.41.2"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.exphem.2025.104799","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T11:12:07Z","timestamp":1746875527000},"page":"104799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Effect of peritransplant measurable residual disease clearance in patients with myelodysplastic neoplasm: a referral center experience"],"prefix":"10.1016","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5038-7093","authenticated-orcid":false,"given":"Kittika","family":"Poonsombudlert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Mott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ratdanai","family":"Yodsuwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1882-0504","authenticated-orcid":false,"given":"Andrew","family":"Vegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Ravindra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prajwal","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1311-6227","authenticated-orcid":false,"given":"Grerk","family":"Sutamtewagul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarida","family":"Magalhaes-Silverman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2025.104799_bib0001","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/hematology.2022000323","article-title":"Achieving MRD negativity in AML: how important is this and how do we get there?","volume":"2022","author":"Hourigan","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.exphem.2025.104799_bib0002","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.20.02308","article-title":"Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2025.104799_bib0003","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.exphem.2025.104799_bib0004","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41408-024-00976-1","article-title":"MRD positivity was the poor prognostic factor for adverse-risk AML patients with allogeneic hematopoietic stem cell transplantation: a multicenter TROPHY study","volume":"14","author":"Cao","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2025.104799_bib0005","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104799_bib0006","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1182\/blood.2021014804","article-title":"Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML","volume":"139","author":"Paras","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104799_bib0007","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41409-018-0300-8","article-title":"The significance of peri-transplantation minimal residual disease assessed by multiparameter flow cytometry on outcomes for adult AML patients receiving haploidentical allografts","volume":"54","author":"Liu","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2025.104799_bib0008","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.104799_bib0009","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104799_bib0010","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.exphem.2025.104799_bib0011","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant. Dec"},{"key":"10.1016\/j.exphem.2025.104799_bib0012","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3324\/haematol.2017.168716","volume":"103","author":"Schmid","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2025.104799_bib0013","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbmt.2015.07.037","article-title":"Management of myelodysplastic syndrome relapsing after allogeneic hematopoietic stem cell transplantation: a study by the French Society of Bone Marrow Transplantation and Cell Therapies","volume":"22","author":"Guieze","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2025.104799_bib0014","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1586\/ehm.10.32","article-title":"Relapse after allogeneic stem cell transplantation","volume":"3","author":"Barrett","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.exphem.2025.104799_bib0015","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.22.01784","article-title":"Real-world validation of molecular international prognostic scoring system for myelodysplastic syndromes","volume":"41","author":"Sauta","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2025.104799_bib0016","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/bloodadvances.2021004367","article-title":"Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations","volume":"5","author":"Heuser","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2025.104799_bib0017","series-title":"American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting","first-page":"e375","article-title":"Hematopoietic cell transplantation for myelodysplastic syndrome","author":"Deeg","year":"2015"},{"key":"10.1016\/j.exphem.2025.104799_bib0018","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/asheducation-2013.1.56","article-title":"Allogeneic transplantation for AML and MDS: GVL versus GVHD and disease recurrence","volume":"2013","author":"van Besien","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.exphem.2025.104799_bib0019","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ajh.25211","volume":"93","author":"Gilleece","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2025.104799_bib0020","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2025.104799_bib0021","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.3390\/cancers14164010","article-title":"Identification of leukemia-associated immunophenotypes by databaseguided flow cytometry provides a highly sensitive and reproducible strategy for the study of measurable residual disease in acute myeloblastic leukemia","volume":"14","author":"Pinero","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.exphem.2025.104799_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.735518","article-title":"Advanced flow cytometry analysis algorithms for optimizing the detection of \"different from normal\" immunophenotypes in acute myeloid blasts","volume":"9","author":"Aanei","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.exphem.2025.104799_bib0023","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.3390\/ijms24054790","article-title":"Targeting measurable residual disease (MRD) in acute myeloid leukemia (AML): moving beyond prognostication","volume":"24","author":"Tiong","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.exphem.2025.104799_bib0024","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/s41409-022-01762-y","article-title":"Pattern of somatic mutation changes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"57","author":"Hong","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.exphem.2025.104799_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.04.014","article-title":"Engrafted donor-derived clonal hematopoiesis after allogenic hematopoietic cell transplantation is associated with chronic graft-versus-host disease requiring immunosuppressive therapy, but no adverse impact on overall survival or relapse","volume":"27","author":"Newell","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.exphem.2025.104799_bib0026","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1182\/bloodadvances.2022009493","article-title":"Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML\/MDS","volume":"7","author":"Loke","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2025.104799_bib0027","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.23.01159","article-title":"Patient-specific measurable residual disease markers predict outcome in patients with myelodysplastic syndrome and related diseases after hematopoietic stem-cell transplantation","volume":"42","author":"Tobiasson","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.exphem.2025.104799_bib0028","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41375-021-01316-z","article-title":"Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns","volume":"36","author":"Bozic","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.104799_bib0029","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/bloodadvances.2022008863","article-title":"Shared graft-versus-leukemia minor histocompatibility antigens in DISCOVeRY-BMT","volume":"7","author":"Olsen","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2025.104799_bib0030","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood.2020009471","article-title":"Clinical effects of administering leukemia-specific donor T cells to patients with AML\/MDS after allogeneic transplant","volume":"137","author":"Lulla","year":"2021","journal-title":"Blood"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X25000906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X25000906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T11:28:20Z","timestamp":1753442900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X25000906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":30,"alternative-id":["S0301472X25000906"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2025.104799","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of peritransplant measurable residual disease clearance in patients with myelodysplastic neoplasm: a referral center experience","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2025.104799","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Experimental Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104799"}}